MARKET

MGNX

MGNX

Macrogenics Inc
NASDAQ
1.960
-0.020
-1.01%
After Hours: 1.980 +0.02 +1.02% 18:20 11/20 EST
OPEN
1.960
PREV CLOSE
1.980
HIGH
2.080
LOW
1.902
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
5.08
52 WEEK LOW
1.320
MARKET CAP
125.26M
P/E (TTM)
-2.4156
1D
5D
1M
3M
1Y
5Y
1D
Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment
Benzinga · 3d ago
Leerink Partners Sticks to Their Buy Rating for MacroGenics (MGNX)
TipRanks · 4d ago
Weekly Report: what happened at MGNX last week (1109-1113)?
Weekly Report · 4d ago
MacroGenics Updates Corporate Presentation With Clinical Program Details
TipRanks · 11/13 22:48
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (TMO), MacroGenics (MGNX) and Diaceutics (OtherDIUXF)
TipRanks · 11/13 17:50
Stifel Nicolaus Sticks to Its Hold Rating for MacroGenics (MGNX)
TipRanks · 11/13 14:05
MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 11/12 21:25
*Macrogenics 3Q Rev $18.7M >MGNX
Dow Jones · 11/12 21:01
More
About MGNX
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.

Webull offers MacroGenics Inc stock information, including NASDAQ: MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.